Celyad Oncology represents a commitment to innovative cell-based therapies for cancer treatment. The company's corporate philosophy revolves around leveraging its expertise in cell engineering and immune-oncology to develop groundbreaking therapies. Celyad Oncology aims to improve patient outcomes and quality of life by delivering personalized and targeted treatments. With a strong focus on research and development, Celyad Oncology strives to stay at the forefront of medical advancements, collaborating with scientific and clinical partners to advance the field of cellular immunotherapy. The company's dedication to scientific rigor and a patient-centric approach drives its pursuit of transformative solutions in the fight against cancer.

Celyad Oncology is primarily present in multiple countries and regions around the globe. With a strong global presence, the company operates in key markets such as Europe, the United States, and Asia. Celyad Oncology's commitment to advancing cell-based therapies extends to various regions, allowing it to reach a wide patient population in pursuit of innovative treatments for various oncology indications.

Celyad Oncology, a leading biopharmaceutical company, has achieved several significant milestones. One notable accomplishment is the successful completion of the Phase 1 THINK trial for CYAD-01, their proprietary NKG2D-based CAR-T therapy. Another achievement includes the initiation of the Phase 1 alloSHRINK trial, evaluating CYAD-101, their first-in-class non-gene edited allogeneic CAR-T candidate. Furthermore, Celyad Oncology has entered into a strategic collaboration with ONO Pharmaceutical Co., Ltd., aiming to develop innovative CAR-T therapies for solid tumors. Additionally, the company has received numerous patents, reinforcing their position as a pioneer in the field of cellular immunotherapy. Celyad Oncology continues to make significant strides in advancing groundbreaking therapies to address unmet medical needs.

Celyad Oncology, a leading biopharmaceutical company, has an intriguing history and background. Founded in 2004, the company is dedicated to developing innovative CAR-T cell-based therapies for the treatment of cancer. Initially known as Cardio3 BioSciences, Celyad Oncology rebranded itself in 2015, putting a greater focus on oncology research. With a strong emphasis on cellular therapy, particularly utilizing its proprietary CAR-T technology, Celyad Oncology aims to revolutionize cancer treatment by engineering T cells to target and destroy cancer cells effectively. Through clinical trials and strategic collaborations, the company strives to provide potential breakthrough solutions for patients battling various forms of cancer worldwide. Celyad Oncology's relentless commitment and expertise drive its pursuit of improved patient outcomes.

The main competitors of Celyad Oncology in the market are bluebird bio, Inc., Fate Therapeutics, Inc., and Cellectis S.A. These companies also operate in the field of cell therapy and are known for their innovative approaches in developing advanced treatments for various diseases. However, Celyad Oncology distinguishes itself with its unique proprietary technologies, such as its allogeneic CAR-T platform and its differentiated shRNA platform. With its strong focus on product development and strategic collaborations, Celyad Oncology continues to position itself as a key player in the competitive landscape of the cell therapy market.

Celyad Oncology is primarily active in the biotechnology and healthcare industries.

Celyad Oncology is a biopharmaceutical company specializing in the development of innovative cancer treatments. The company's business model focuses on utilizing its proprietary CAR-T cell platform to engineer T-cells to target and destroy cancer cells. Through extensive research and clinical trials, Celyad aims to address unmet medical needs and improve patient outcomes by developing personalized immunotherapies. By leveraging its expertise in cell therapy and strategic partnerships, Celyad Oncology strives to revolutionize cancer treatment and provide hope for patients worldwide.

Celyad Oncology KGV ir 0,87.

Celyad Oncology KUV ir 0,09.

AlleAktien kvalitātes vērtējums Celyad Oncology ir 3/10.

gaidāmā Celyad Oncology apgrozījums ir 156,25 milj. EUR.

gaidāmā Celyad Oncology peļņa ir 15,41 milj. EUR.

Celyad Oncology is an innovative biotechnology company focused on the development of cancer therapies. Its business model is centered around researching new treatment options to fight cancer. Celyad Oncology has various divisions that engage in research, development, production, and marketing of therapeutic products. One of its key divisions is CAR-T technology, which involves modifying a patient's T-cells to specifically recognize and kill cancer cells. The company is dedicated to optimizing the potential of this therapy through innovative technologies. Additionally, Celyad Oncology is involved in researching and developing other cancer treatment options such as allogeneic stem cell transplantation and the use of TCR-T cells. The company collaborates with leading research institutions and other companies to drive innovation in cancer treatment. Celyad Oncology is also involved in the production and marketing of therapeutic products, including CYAD-01, a treatment for metastatic colorectal and esophageal cancer. The company continuously strives to expand and enhance its portfolio of therapies in order to provide better healthcare to patients worldwide. Its business model relies on collaboration with other companies and institutions to advance cancer treatment. One of its key partnerships is with Novartis, a leading healthcare company, to jointly develop and market cancer therapies for the benefit of cancer patients. In summary, Celyad Oncology's business model is focused on the research, development, production, and marketing of cancer therapies. The company has various divisions dedicated to the exploration and development of new treatment options, and it already offers innovative products for cancer treatment. Celyad Oncology works closely with other companies and institutions to advance cancer treatment and provide better healthcare to patients worldwide.

Celyad Oncology izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Celyad Oncology vai uzņēmums nedod dividendes.

Celyad Oncology ISIN ir BE0974260896.

Celyad Oncology WKN ir A1W7Q9.

Celyad Oncology simbols ir CYAD.BR.

Pēdējo 12 mēnešu laikā Celyad Oncology maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Celyad Oncology plāno maksāt dividendes 0 EUR apmērā.

Celyad Oncology pašreizējā dividendu rentabilitāte ir .

Celyad Oncology maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Celyad Oncology pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Celyad Oncology tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Celyad Oncology apmērā 0 EUR, kas tika izmaksāta 5.03.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 5.03.2025..

Pēdējās dividendes izmaksa notika 5.03.2025..

Gadā 2024, Celyad Oncology izmaksāja 0 EUR dividendes.

Celyad Oncology dividendes tiek izmaksātas EUR.